Company: BLCO
Filing Date: 2025-10-29
Form Type: 10-Q
Source: 0001860742-25-000023
Chunk: 54

Company: Bausch & Lomb Corp
Filing Date: 2025-10-29
Form: 10-Q
Item: Item 8
Chunk 54
---
)(146)Amortization of intangible assets(68)(72)Other income (expense), net15 (22)Operating income95 43 Interest income3 4 Interest expense(101)(100)Loss on extinguishment of debt3 — Foreign exchange and other (3)(5)Loss before provision for income taxes$(3)$(58)

30

Vision CarePharmaceuticalsSurgicalTotalNine Months Ended September 30,(in millions)20252024202520242025202420252024RevenuesProduct Sales$2,139 $2,010 $902 $881 $641 $608 $3,682 $3,499 Other Revenues6 6 4 2 4 4 14 12 2,145 2,016 906 883 645 612 3,696 3,511 ExpensesCost of goods sold (excluding amortization and impairments of intangible assets)820 735 303 274 390 360 Cost of other revenues— — 4 2 — — Selling, general and administrative689 674 439 385 218 195 Research and development34 36 36 22 34 29 Segment Profit$602 $571 $124 $200 $3 $28 729 799 Corporate(497)(459)Amortization of intangible assets(202)(220)Other expense, net(29)(45)Operating income1 75 Interest income9 10 Interest expense(323)(301)Loss on extinguishment of debt(6)— Foreign exchange and other (11)(8)Loss before provision for income taxes$(330)$(224)Revenues by Segment and by Product CategoryRevenues by segment and product category were as follows:Vision CarePharmaceuticalsSurgicalTotalThree Months Ended September 30,(in millions)20252024202520242025202420252024Pharmaceuticals$1 $1 $279 $246 $— $— $280 $247 Devices270 250 — — 214 205 484 455 OTC454 420 — — — — 454 420 Branded and Other Generics9 11 50 59 — — 59 70 Other revenues2 2 1 1